manage your blood sugar and protect your liver health with glucevia®
TRANSCRIPT
Manage your blood sugar and protect your liver health with Glucevia®
Clinical studies
Randomized, double blind, placebo controlled, cross over, acute study: Visen et al, 2009
7-week randomized, double blinded, placebo controlled, cross over study: Zulet et al, 2014
Efficacy studies: pre-clinical data
High fat diet model: Ibarra et al, 2011
Obesity model: Monto et al, 2014
Diabetic model: Gomez et al, 2015
Safety and toxicology
Glucevia® research programPUBLIS
HED
Fatty liver and steatosis
Wiernsperger, 2013
Steatosis is excessive fat accumulation in the form of triglycerides in the liver: > 5% of hepatocytes that contain lipid droplets
Prevalence rate of 30% in the general population
Could progress towards a more severe form with inflammation and fibrosis: Non-Alcoholic Steatohepatitis (NASH)
Nonalcoholic Fatty Liver Disease (NAFLD)
World Gastroenterology Organisation, 2012http://www.centre-hepato-biliaire.org
Animals: BKS (db/db) female mice (5 weeks of age)
Design 7 months administration of:
Control diet (n=10) Diet with Glucevia (0,7g/kg of diet) (n=10)
Variables: Metabolic blood parameters (glucose, insulin,
cholesterol, triglycerides) Histological analyses of liver NAFLD blood parameters
5
Glucevia® a natural solution
Protocol: diabetic model
Journal of Diabetes & Metabolism, 2015; Vol 4(Issue 6)
-54%
Glucevia® significantly reduces fatty liver tissue and improved markers of healthy liver in diabetic animals after 7 months
Results: diabetic model
Micrographs of H&E (high) or Oil red O (down) stained sections of livers from diabetic mice administered control or Glucevia
Glucevia® control
Journal of Diabetes & Metabolism, 2015; Vol 4(Issue 6)
Glucevia® a natural solution
Diabetic model
Insulin was significantly reduced after 7 months as well as the HOMA-IR parameter showing reduced insulin-resistance in diabetic animals after administration of Glucevia (p<0.05)
Control Glucevia®
Initial Fasting Blood Glucose (mg/dl) 202.17 ± 28.39 202.00 ±56.20
Final Fasting Blood Glucose (mg/dl) 791.25 ± 140.44 726.31 ± 127.63
Insulin (mU/L) 5.60 ± 0.82 4.39 ± 1.50*
HOMA-IR 9.55 ± 1.33 5.36 ± 2.53*
Total cholesterol (mg/dl) 143.63 ± 24.77 133.12 ± 36.43
HDL-C (mg/dl) 88.00 ± 21.07 88.81 ± 35.05
Triglycerides (mg/dl) 264.83 ± 49.35 162.72 ± 73.90*
Adiponectin (µg/ml) 10.67 ± 1.79 13.14 ± 0.06
* p < 0.05
Journal of Diabetes & Metabolism, 2015; Vol 4(Issue 6)
Results: diabetic model
Suggested mechanisms of action for Glucevia
Effect on the liver and mechanism of action
Key takeaways
The last pre-clinical study on Glucevia ® recently published in the Journal of Diabetes and Metabolism shows:
Glucevia ® helps manage blood sugar levels and protects liver health, thus addressing 2 main issues for people at risk of prediabetes and/or metabolic syndrome.
Due to its hepato-protective effect, Glucevia ® could be a new and effective natural solution for preventing steatosis and non-alcoholic fatty liver disease.